Novel therapeutic could treat neurodegenerative diseases
A novel therapeutic could improve memory, cognitive function and neuroinflammation in neurodegenerative diseases.
VNA-318, developed by biotechnology company Vandria, was tested in preclinical mouse models of neurodegeneration and cognitive impairment. Data shows the candidate created an immediate improvement in memory, learning and cognitive function, as well as long-term reduction in neuroinflammation, reduced toxic protein aggregation and improved mitochondrial function.
VNA-318 is a first-in-class, orally bioavailable, and brain-penetrant small molecule targeting a novel protein with a dual mode of action (MoA). Initially, VNA-318 is being developed to address the major unmet medical needs facing patients with Alzheimer’s disease, particularly cognitive impairment and the debilitating loss of function associated with it. Given its broad MoA, however, VNA-318 has potential to treat other Central Nervus System (CNS) diseases.
The drug candidate has been advanced to a Phase I randomised, double-blind, single and multiple ascending dose study in humans. Interim results show excellent safety and tolerability of VNA-318 with no serious adverse events and no adverse events leading to trial discontinuation.
“We are very excited about the results of our first-in-human trial of VNA-318, which ticks all the boxes for a Phase I trial – and more,” said Klaus Dugi, CEO of Vandria.
“The statistically significant dose-dependent change in a key target engagement biomarker is a very important finding and will be valuable for our Phase II clinical development strategy.
“This, coupled with safety, tolerability and demonstrated brain penetration, as well as pre-clinical data strongly support VNA-318’s advancement in Alzheimer’s disease.
“We believe that VNA-318 has the potential to address unmet medical needs like mild cognitive impairment associated with Alzheimer’s and Major Depressive Disorder, as well as other CNS disorders.”
Vandria is planning to raise a Series B in 2026 to fund proof-of-concept Phase II trials.
Bruno Quinney, Content Team, DDW
